Collagen-IN-1 (compound 3) is an ortho-carbonyl hydroquinone derivative exhibiting selective inhibition of collagen. It non-competitively inhibits agonist-induced platelet aggregation, with an IC50 value of 1.77 μM. Collagen-IN-1 effectively reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelets. This compound holds promise for research into platelet-related thrombosis diseases [1].
Collagen type IV alpha1 (531-543) is a protein that in humans is encoded by the COL4A1 gene on chromosome 13. It is ubiquitously expressed in many tissues and cell types. COL4A1 is a subunit of type IV collagen and plays a role in angiogenesis.
Collagenase Type I 是一种蛋白水解酶,主要靶点是胶原蛋白,能够分解胶原蛋白中的肽键。Collagenase 作为一种潜在的治疗选择来分解突出的椎间盘物质,从而减少对附近神经的压迫。Collagenase 可能有助于过度疤痕组织的分解和重组,潜在地改善组织功能和外观。Collagenase 具有治疗椎间盘突出、瘢痕疙瘩、脂肪团、脂肪瘤以及佩罗尼氏病和手掌纤维瘤病等方面的潜力。
JTE-952 is a oral, potent active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse